A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
Public ClinicalTrials.gov record NCT06736262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.
Study identification
- NCT ID
- NCT06736262
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 67 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2024 (Actual)
- Primary completion
- Jul 21, 2026 (Actual)
- Completion
- Jul 21, 2026 (Actual)
- Last update posted
- Aug 6, 2026
2024 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site 118 | Birmingham | Alabama | 35244 | — |
| Investigative Site 108 | Little Rock | Arkansas | 72205 | — |
| Investigative Site 105 | San Diego | California | 92123 | — |
| Investigative Site 116 | Tampa | Florida | 33613 | — |
| Investigative Site 109 | Boise | Idaho | 83706 | — |
| Investigative Site 124 | Normal | Illinois | 61761 | — |
| Investigative Site 110 | Indianapolis | Indiana | 46250 | — |
| Investigative Site 123 | Lafayette | Louisiana | 70508 | — |
| Investigative Site 101 | Baltimore | Maryland | 21224 | — |
| Investigative Site 121 | White Marsh | Maryland | 21162 | — |
| Investigative Site 103 | Cincinnati | Ohio | 45236 | — |
| Investigative Site 111 | Murray | Utah | 84107 | — |
| Investigative Site 115 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06736262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06736262 live on ClinicalTrials.gov.